Date: 2014-09-11
Type of information: Pipeline acquisition
Acquired company: PharmEste\'s TRPA1 research assets (Italy)
Acquiring company: Ario Pharma (UK)
Amount: undisclosed
Terms: * On September 11, 2014, Ario Pharma, a Cambridge biopharmaceutical company developing innovative new approaches to treat respiratory disease, announced has acquired the TRPA1 antagonist research programme previously owned by PharmEste.
Details: The acquired assets include a series of small molecule TRPA1 antagonists, patents, know-how and data that adds significantly to Ario Pharma\'s existing TRPA1 chemistry portfolio. The TRPA1 target has been shown to have application across inflammatory diseases including asthma, cough, COPD and pain. Ario Pharma is planning to undertake a TRPA1 lead optimisation project, focusing on orally available TRPA1 antagonist small molecules for treatment of asthma. The chemistry from PharmEste has already demonstrated excellent in vivo efficacy in pain models. Ario Pharma is also actively seeking partners for its TRPA1 programme, for all indications.
Related: Allergic diseases Respiratory diseases
